Modulation of Gut Microbiota in Pathological States

Wang, Yulan; Wang, Baohong; Wu, Junfang; Jiang, Xiangyang; Tang, Huiru; Nielsen, Ole Haagen

Published in:
Engineering

DOI:
10.1016/J.ENG.2017.01.013

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Wang, Y., Wang, B., Wu, J., Jiang, X., Tang, H., & Nielsen, O. H. (2017). Modulation of Gut Microbiota in Pathological States. DOI: 10.1016/J.ENG.2017.01.013
The human microbiota is an aggregate of microorganisms residing in the human body, mostly in the gastrointestinal tract (GIT). Our gut microbiota evolves with us and plays a pivotal role in human health and disease. In recent years, the microbiota has gained increasing attention due to its impact on host metabolism, physiology, and immune system development, but also because the perturbation of the microbiota may result in a number of diseases. The gut microbiota may be linked to malignancies such as gastric cancer and colorectal cancer. It may also be linked to disorders such as nonalcoholic fatty liver disease (NAFLD); obesity and diabetes, which are characterized as “lifestyle diseases” of the industrialized world; coronary heart disease; and neurological disorders. Although the revolution in molecular technologies has provided us with the necessary tools to study the gut microbiota more accurately, we need to elucidate the relationships between the gut microbiota and several human pathologies more precisely, as understanding the impact that the microbiota plays in various diseases is fundamental for the development of novel therapeutic strategies. Therefore, the aim of this review is to provide the reader with an updated overview of the importance of the gut microbiota for human health and the potential to manipulate gut microbial composition for purposes such as the treatment of antibiotic-resistant Clostridium difficile (C. difficile) infections. The concept of altering the gut community by microbial intervention in an effort to improve health is currently in its infancy. However, the therapeutic implications appear to be very great. Thus, the removal of harmful organisms and the enrichment of beneficial microbes may protect our health, and such efforts will pave the way for the development of more rational treatment options in the future.

© 2017 THE AUTHORS. Published by Elsevier LTD on behalf of the Chinese Academy of Engineering and Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
amniotic fluid, and meconium [4–7]. Although gut microbes are phylogenetically conserved [8], the composition of human gut microbes can be affected by the host's personal hygiene, diet, drug intake, and disease status throughout his or her life [9,10]. These effects are more profound during the early life stages, when initial microbial colonization begins; however, the stability and homeostasis of gut microbes are usually established once the host is between 2–5 years of age [11].

In recent years, gut microbes have been gaining increasing attention due to their impact on human health [12]. The composition and function of our gut microbes appear to play an essential role in almost every biological process in the body. It has long been recognized that gut microbes can help their host to defend against pathogens, develop a healthy intestinal structure and immune system, and aid with the digestion of indigestible dietary fibers [13]. More recently, associations have also been recognized between gut microbes and diseases such as fatty liver disease, coronary heart disease, cancer, and obesity and diabetes [14]. In this review, we summarize and provide the most recent facts on the roles of gut microbes in human health, along with the unmet need for and solutions toward modulating the gut microbiota.

2. The function of gut microbes in human health

Gut microbes can coexist symbiotically with a healthy human. Short-chain fatty acids (SCFAs), including butyrate, acetate, and propionate, are fermentation products of dietary fibers produced by gut microbes. Although such fibers are otherwise indigestible by humans, their metabolites provide essential nutrients for colonic cells and play an important role in maintaining gut health. *Eubacterium hallii* (*E. hallii*) is considered to be an SCFA-producing microbe, and a recent discovery indicates that *E. hallii* is capable of producing high levels of glycerol/diol dehydratase, a key enzyme in the conversion of glycerol to 3-hydroxypropionaldehyde, a process that also produces cobalamin [15]. Levels of serotonin, a neurotransmitter synthesized in colonic enterochromaffin cells that is known to regulate a wide range of physiological activities such as enteric motor and platelet function, are regulated by the ingestion of spore-forming bacteria, mainly consisting of clostridial species [16]. Other studies have also investigated the relationship between gut microbes and gut metabolites.

Gut microbes are thought to metabolize phenyl-containing amino acids, such as tryptophan. Levels of tryptophan metabolites, such as indoxyl sulfate and indole-3-propionic acid, are highly correlated to the presence of gut microbes [17]. The production of indole-3-propionic acid is dependent on the colonization of the bacterium *Clostridium sporogenes* [17]. Furthermore, variations in *Faecalibacterium prausnitzii* colonies have been associated with levels of urinary metabolites involved in multiple metabolic pathways [18]. One such association has been identified between *Clostridium difficile* (*C. difficile*) and levels of fecal cholesterol and coprostanol, indicating that gut microbes play a crucial role in lipid metabolism [19]. Taken together, these studies highlight the essential role of gut microbes in maintaining normal physiology in humans. A deviation from the normal gut ecosystem could therefore be associated with a range of abnormalities, such as cancer, nonalcoholic fatty liver disease (NAFLD), obesity and diabetes, coronary heart disease, kidney dysfunction, and neurodegenerative diseases (Fig. 1); these associations will be summarized in the forthcoming sections.

2.1. Cancer

Levels of *Helicobacter pylori* are widely associated with an increased risk of gastric [20] and colorectal cancer [21]. A Gram-negative bacterium resides in the human stomach and can cause various diseases including gastritis, peptic ulcer, and gastric cancer [21]. Other resident gut microbes have also been identified as major factors in the increased risk of human colon cancer, including *Streptococcus bovis* [22,23], *Bacteroides fragilis* [24], and *Escherichia coli* (*E. coli*) [25]. These bacteria can cause inflammation and may trigger inflammatory bowel disease, thereby promoting the development of colorectal cancer. The proposed mechanism for this increased risk is recognized as involving Toll-like receptors (TLRs) and triggering downstream signaling pathways such as NF-κB, ERK, JNK, and p38, leading to an up-regulation of the growth factors and inflammatory mediators that promote neoplasia [26].

2.2. Nonalcoholic fatty liver disease

NAFLD is the most common chronic liver condition in both Western [27] and Asian [28] countries, and is considered to be a hepatic manifestation of metabolic syndrome. Due to its close link with obesity, the pathogenesis of NAFLD has been widely accepted to be the result of multiple “hits,” including the contribution of the intestinal dysbiosis that is associated with obesity [29,30].

Studies show that a shift in the gut microbe composition is associated with obesity, and correlates closely with the prevalence and progress of NAFLD [31–34]. Zhu et al. [34] have suggested that the connection between gut-derived endogenous alcoholic and nonalcoholic steatohepatitis (NASH) might be involved in the pathogenesis of obesity in children. A significant compositional shift in gut microbes, such as the decrease of some selected members of Firmicutes, has been observed in patients with NAFLD [33]. A decrease in Bacteroidetes has also been found among obese patients with NASH compared with healthy controls [34]. In addition, Wang et al. [30] assessed the fecal microbial composition and its correlation with liver biochemistry in non-obese adult patients with NAFLD. Bourlier et al. [35] have suggested that the severity of NAFLD is associated with gut dysbiosis along with a shift in metabolic function of the gut microbiota. Bourlier et al. [35] also revealed that *Bacteroides* and *Ruminococcus* are independently associated with NASH and significant fibrosis, respectively. These studies indicate that an alteration in the composition of the gut microbiota is closely associated with the development of NAFLD.

Several different mechanisms have been uncovered that relate to gut microbe composition and the pathogenesis of NAFLD. Firstly, gut microbes have the potential to increase energy extraction from ingested food [36]; alter appetite signaling [37,38]; and enhance the expression of genes involved in de novo lipogenesis, β-oxidation, or inflammation-driven liver steatosis [39,40]. Secondly, gut microbes and the translocation of gut-derived bacteria or metabolites are likely to influence the development of hepatic inflammation [41,42]. Small intestinal bacterial overgrowth

![Fig. 1. Summary of the role of gut microbes and their modulation in a pathological state.](image-url)
syndrome (SIBOS) is highly prevalent in patients with NAFLD [43], which appears to be related to an increased gut permeability in these patients [44]. Intestinal permeability plays an important role in the pathogenesis of NAFLD, which in turn leads to hepato-cellular inflammation [44,45] and insulin resistance [32,39]. It is notable that the expression levels of the lipopolysaccharide (LPS) receptor, CD14, and of TLR-4 are also higher in NASH patients with SIBOS [46]. This finding suggests that SIBOS, and particularly its Gram-negative bacteria population, promotes the progression of NASH through TLR-4. Research has indicated that an up-regulation of CD14 in Kupffer cells is related to a hepatic hyper-inflammatory response to LPS during NASH progression [47].

2.3. Obesity and diabetes

A large body of evidence from both population and animal studies indicates that alterations in the gut microbiome composition are associated with obesity and type II diabetes (T2D). For example, Bäckhed et al. [48] showed that wild-type mice gained 40% more body weight than germ-free mice, although germ-free mice consumed 29% more food, while re-conventionalized germ-free mice gained 57% in body weight. This observation led to increased interest in investigating the composition of gut microbes in obese mice. Studies have shown that microbe composition in obese mice (ob/ob) is reduced by 50% in the presence of high levels of Bacteroidetes and Firmicutes, as compared with that in corresponding lean mice [49]. Further evidence revealed that diet-induced obesity may produce rich levels of Firmicutes, specifically in the Mollicutes class. In addition, lean germ-free mice receiving gut microbes from diet-induced obese mice have more fat depositions than those receiving from lean donors [50]. The effect of lean-like gut microbe transplantation is equally significant for obese mice when they are co-housed with lean mice, with the composition of the gut microbes of obese mice containing more Bacteroidetes when such mice are co-housed with lean mice [51].

Population studies have also highlighted the association between gut microbe composition and obesity. Turnbaugh et al. [50] showed that human obesity was associated with alterations in levels of Bacteroidetes and Firmicutes. It is notable that obesity-associated microbes from humans can be transferred to germ-free mice, resulting in significantly increased body fat as compared with germ-free mice colonized with lean microbes [36]. The transferable colonization of fat- or lean-associated microbes has been confirmed by Zhang and coworkers [52]. Obese children and/or children predisposed to obesity, such as those with Prader-Willi syndrome, are subjected to a diet rich in non-digestible carbohydrates in order to induce weight loss [53]. Germ-free mice colonized with pre-intervention gut microbes showed larger body fat accumulation as compared with mice with post-intervention gut microbes [52]. Alterations of gut microbe composition are also associated with T2D [54]. An overall decrease in proportions of phylum Firmicutes and class Clostridia is presented in diabetic patients, which is in contrast to gut microbes found in obese patients [55]. In addition, Clostridium species and Lactobacillus species appear to be important in driving T2D [56]. The range of SCFA-producing bacteria is low in the diabetic population as compared with a healthy background population [3].

The link between gut microbe composition and obesity is believed to be mediated by the metabolic function of the gut microbes. That is, gut microbes produce SCFAs, which provide essential nutrients and energy for maintaining a healthy and intact gut barrier. Without these gut microbes, the GIT becomes defective, possibly due to the lack of essential SCFAs. Such a defective gut structure may inhibit the delivery of nutrients to the liver, stopping them from being converted into fat for deposition. Another important function of gut microbes is the modulation of lipid absorption. This process is achieved via the action of gut microbes that are capable of removing polar groups of glycine and taurine from bile acids, leading to less fat being emulsified and absorbed from the GIT. De-conjugated bile acids are therefore absorbed by the host, affecting cholesterol metabolism [57,58]. Kishino et al. [59] identified genes in the gut bacterium Lactobacillus plantarum that encode for the enzymes involved in the saturation metabolism of polyunsaturated fatty acids.

2.4. Coronary heart disease

Gut microbes associated with obesity and T2D may promote coronary heart disease. In addition, bacterial DNA is found in human atherosclerotic samples; to be specific, Chryseemonas is present in human atherosclerotic samples, and Veillonella and Streptococcus are found in the majority of atherosclerotic samples, as well as in the oral cavity and gut of the same patients [60]. This evidence indicates that the presence of these gut microbes correlates directly with coronary heart disease. Another population study involving 893 participants constructed a novel model demonstrating that 26% of high-density lipoproteins are attributed to the gut microbiome, independent of age, sex, and host genetics [61]. Gut microbes modulating lipid metabolism and cholesterol via bile acids provide a possible mechanism for the relationship between gut microbes and coronary heart disease. A link between coronary heart disease and the microbial metabolism of dietary choline and L-carnitine has already been established [62,63]. Both choline and L-carnitine can be metabolized by gut microbes, producing trimethylamine (TMA), which is then further metabolized in the liver into trimethylamine-N-oxide (TMAO). TMAO has been recognized as a pro-atherogenic agent [64]. The underlying mechanism that describes the association between TMAO-producing gut microbes and coronary heart disease is attributed to the action of a TMAO-producing enzyme, flavin monoxygenase-3, which is involved in the perturbations of reverse cholesterol transport and which has the effect of reorganizing the total cholesterol balance of the body [65,66]. Further evidence has shown that targeting the gut microbial production of TMA with a non-lethal microbial inhibitor, 3,3-dimethyl-1-butanol, could reduce the levels of TMAO and prevent atherosclerotic lesion [67].

2.5. Neurodegenerative diseases

Increasing evidence is revealing the involvement of gut microbes in modulating neurological diseases via a bidirectional microbiota-gut-brain axis [68]. In experiments, germ-free mice exhibited increased motor activity and reduced anxiety-like behavior compared with conventional specific pathogen-free mice [69]. The germ-free mice also expressed lower mRNA levels of hippocampal serotonin 1A receptor and amygdala N-methyl-D-aspartate receptor (NMDAR) subunit NR2B [70], and higher levels of the brain-derived neurotrophic factor (BDNF) in the dentate granule layer of the hippocampus [70]. Other studies have found that colonization with Clostridium butyricum can restore cognitive defects [71]. Administration of Lactobacillus farcinimis [72], Lactobacillus reuteri [73], Bacteroides fragilis [74], or Lactobacillus rhamnosus strains [75,76] could also potentially prevent stress-induced social deficit and reduce the levels of stress-induced plasma corticosterone in mice [76], suggesting that the gut microbiota could be a potential therapeutic target for neurodegenerative diseases. This result was verified by Möhle et al. [77], who used a broad spectrum of antibiotics (such as ampicillin and vancomycin)
to treat adult mice with neurodegenerative diseases. Their study concluded that antibiotic treatment decreased hippocampal neurogenesis and memory retention from neuronal progenitors, and that recognition tests were affected. These deficits were, however, fully restored in mice fed with a mixture of eight probiotics, namely Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus [77]. It is notable that all of these probiotic modulations were similar in vagotomized mice, demonstrating that the vagus is a major modulatory constitutive communication pathway in connecting bacteria, gut, and brain [76].

Neuroinflammation is likely to be closely linked with multiple pseudo-degenerative pathways involved in neurodegenerative diseases [78]. The compositions of fecal microbiota from patients with Parkinson’s disease exhibited decreased “anti-inflammatory” butyrate-producing bacteria, such as Blautia, Coprococcus, and Roseburia, whereas the mucosal microbiota displayed reduced levels of Faecalibacterium [79]. Such colonic dysbiosis with a lower abundance of fecal E. coli and Butyrivibrio fibrisolvens was also reported in an amyotrophic lateral sclerosis mouse model [80], implying that bacteria may play a crucial role in the neuroinflammation of neurodegenerative diseases. More evidence for the presence of a gut-brain axis comes from studies on the modulation of gut microbes on neurotransmitters. Barrett et al. [81] revealed that microaerophilic Lactobacillus and Bifidobacterium species were capable of metabolizing glutamate into gamma amino butyric acid (GABA). Furthermore, Cyanobacteria have been reported to produce neurotoxins such as β-N-methylamino-L-alanine (BMAA) that contribute to various neurological dysfunctions [82].

3. Modulation of gut microbes

3.1. Dietary modulation of gut microbiome composition

Gut microbes are increasingly being recognized as a forgotten “organ” that plays a crucial role in disease development. Questions remain as to how microbes can be manipulated in order to maintain good health. Food intake appears to be the first treatment of choice in modulating gut microbes. Amato et al. [83] showed that a Western diet may result in increased levels of Firmicutes and reduced levels of Prevotella, which are both associated with obesity and T2D. In animal models, levels of Firmicutes and Bacteroidetes are closely associated with a high-fat diet [84]. Four weeks of continuous intake of a high-fat diet has been shown to induce an increased abundance of Firmicutes and a decreased abundance of Tenericutes. Reduced levels of Bacteroidetes occur after eight weeks of continuous intake of a high-fat diet [84]. Modification of the resulting unhealthy gut, using a vegetarian diet or probiotics, may be achieved by providing nutrients that are favored by some bacteria groups, such as Prevotella [85]. Interventions with four days of a meat-based or vegetable-based diet have been shown to change the composition of gut microbes extensively. For example, an increased abundance of bacteria involved in amino acid fermentation, such as Alistipes putredinis, Bilophila, and Bacteroides, is associated with a meat-based diet, whereas bacteria involved in carbohydrate fermentation, such as Roseburia, Eubacterium rectale, Ruminococcus bromii, and Faecalibacterium prausnitzii, are associated with a vegetable-based diet [85]. Recent studies into the correlations between gut microbes and 126 exogenous and intrinsic host factors, such as disease states and dietary factors, have identified a positive correlation between a high-carbohydrate diet and high levels of Bifidobacterium, but a negative correlation between a high-carbohydrate diet and Lactobacillus, Streptococcus, and Roseburia species [86]. Furthermore, red wine consumption is associated with increased levels of Faecalibacterium prausnitzii, which is known to have an anti-inflammatory effect [87].

Prebiotics, such as dietary fibers and some oligosaccharides, have been shown to have beneficial effects on human health [88]. Changes in gut microbes as associated with ingestion of prebiotics have been widely reported. For example, a 10-fold increase in fecal Bifidobacteria has been demonstrated in people who have received oligosaccharides intervention as compared with a placebo control group [89,90]. Furthermore, probiotics supplementation appears to be more effective in infants than in adults [91], a result that is largely due to the gut microbial community, which may have a greater impact on infants since it is under development at that age, resulting in a more easily manipulated effect. Thus, an increased abundance of Lactobacillaceae and Bifidobacteriaceae species has been found in children supplemented with Lactobacillus rhamnosus GG (LGG) [92]. In addition, LGG supplementation induces increased levels of Lactococcus and Lactobacillus, along with a decrease in E. coli in pre-school children [93].

3.2. Drugs modulate gut microbe composition

Antibiotic treatment is used to treat pathogenic infections, and is shown to have profound effects on the gut microbiota. Zhao et al. [94] reported that treating mice with gentamicin and ceftriaxone induces decreased levels of Barnesiella, Prevotella, and Alistipes, albeit with increased levels of Bacteroides, Enterococcus, Erysipelotrichaceae incertae sedis, and Mycoplasma. In addition, mouse models have shown that this treatment can cause a decrease in a range of metabolites, including SCFAs, amino acids, and primary bile acid, and an increase in oligosaccharides, choline, and secondary bile acids [94].

Responses to antibiotic treatment vary between individuals. Analyses of gut microbes over a 10-month period of three individuals who received two courses of ciprofloxacin suggest that the gut microbial community is relatively stable and has limited day-to-day variability, and that large inter-person variations are prominent in the gut microbial community [95]. Moreover, antibiotic treatment results in a rapid shift of the gut microbial community during the course of the treatment, mainly manifested as a loss of microbial diversity. Despite the recovery in the levels of major microbial colonies after a week of antibiotic withdrawal, these levels are not fully restored [85]. This finding reveals that the gut community is resistant to changes unless it experiences repeated perturbations in the long term. Many herbal medicines are rich in polyphenols, which must interact with gut microbes in order to become bioavailable and bioactive [96], and which could modulate the gut microbial community. In addition, herbal medicines often exert mild anti-bacterial effects [97] and, if used over a long-term period, may permanently modulate the gut microbial community. Thus, there is a huge potential for managing diseases through the modulation of gut microbes.

3.3. Fecal transplantation modulates gut microbe composition

The first description of a fecal microbiota-transplantation (FMT) in the treatment of C. difficile occurred in 1958 [98]. There has been a recent increase in the use of fecal transplantation for modulating the gut microbial community and eliminating C. difficile colonies. Fecal transplantation treatment for C. difficile appears to be effective: 81% of C. difficile infection cases were resolved after the first FMT treatment [99]. This result has been reproduced in a clinical
trial of 232 Canadian patients infected with C. difficile, showing that stool preparation methods (freshly prepared vs. frozen) actually had no effect on the outcome of the significance in altering the gut microbial community [100]. This observation demonstrates the benefit of a frozen sample preparation, in which safety measures could be put in place prior to the treatment of patients. The gut microbial communities of donors and their respective recipients are closely correlated soon after the transplantation, but may deviate from each other over time. Thus, populations of Bacteroidetes and Firmicutes in FMT recipients have been shown to increase to levels that are equivalent to those of fecal donors, whereas the levels of C. difficile have been shown to decrease from 4% to 0.2% in FMT recipients [99]. Other microbial alterations have also been associated with fecal transplantation, including the shift from Proteobacteria to Firmicutes and Bacteroidetes dominant species [101–103]. Given the stability of the gut microbial community [95], it may be important for patients infected with C. difficile to receive multiple fecal transplantations in order to establish a healthy microbial system over the long term.

4. Future perspectives

This review covered some typical studies on the association between gut microbes and various disease states as well as methods to modulate the composition of gut microbes. It is not our intention to be comprehensive, but rather to highlight some recent and outstanding research publications. At this point, it is evident that gut microbes have a considerable impact on human health. Research has revealed that the gut microbial community may be modulated by various methods, such as food, drugs, and fecal transplantation. It has accordingly become necessary to define the microbial composition of a healthy gut, and to learn how individual characteristics (age, gender, and ethnicity) may affect the composition of the gut microbiota. Given the intrinsic stability of our gut microbial community, long-term interventional follow-up may become necessary as well.

However, more insight is needed into the mechanisms of the action of gut microbes, which are often mediated by metabolites such as bile acids, SCFAs, and choline. The specific microbes responsible for such actions still remain unclear, but are necessary for specific gut microbial modulation. Despite extensive research into correlations between levels of metabolites and specific gut microbes [18], the causative factor of gut microbes in various diseases is not yet clarified. Therefore, investigating these underlying molecular mechanisms remains as an important focus in future research, and will require concerted efforts from scholars in multidisciplinary areas of research, including clinical microbiologists, molecular biologists, and chemical biologists. Finally, novel emerging research on the role of gut microbes in neurodegenerative diseases presents an area of especially unmet need; particular attention is required on how gut microbes and their metabolites can access the brain and affect various neurological functions in humans.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (21375144 and 21105115) and the National Basic Research Program of China (2012CB934004).

Compliance with ethics guidelines

Yulan Wang, Baohong Wang, Junfang Wu, Xiangyang Jiang, Huiru Tang, and Ole H. Nielsen declare that they have no conflict of interest or financial conflicts to disclose.

References

[1] Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci USA 2003;100(18):10452–9.
[2] Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016;14(8):e1002533.
[3] Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012;490(7418):55–60.
[4] Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placaenta harbors a unique microbiome. Sci Transl Med 2014;6(237):237ra65.
[5] Ardissone AN, de la Cruz DM, Davos-Richardson AG, Rechcigl KT, Li N, Drew JC, et al. Meconium microbiome analysis identifies bacteria correlated with premature birth. PLoS One 2014;9(3):e90784. Erratum in: PLoS One 2014;9(6):e101399.
[6] Bobbit JR, Ledger WJ. Unrecognized amionitosis and prematurity: a preliminary report. J Reprod Med 1977;19:8–12.
[7] Mole H, Gómez M, Helg H, Bus LM, Gómez M, Li M, Wu J, et al. Bacterial diversity in meconium of preterm neonates and evolution of their fecal microbiota within the first month of life. PLoS One 2013;8(6):e66986.
[8] Martin JN, Jones SE, Leofin J, Artin KY. Microbiomes in light of traits: a phylogenetic perspective. Science 2015;350(6261):aac9323.
[9] Loozepa CA, Stombaugh JI, Gordon JI, Jansson JK. Gritition, Diverse, Resilience and resilience of the human gut microbiota. Nature 2012;489(7415):220–30.
[10] Maslowskí KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol 2011;12(1):5–9.
[11] Rodriguez JM, Murphy K, Stanton C, Ross RP, Koberol O, Juge N, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis 2015;26:26050.
[12] Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016;375(24):2369–79.
[13] Kelly D, Campbell JL, King TP, Grant G, Jansson EA, Couats AGP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-acyltransferase shuttling of PPAR-y and RelA. Nat Immunol 2014;5(1):104–12.
[14] Boulanger CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med 2016;8:42.
[15] Engels C, Ruscheweyh HJ, Beerwinkel N, Lacroix M, Schwab C. The common gut microbe Eubacterium hallii also contributes to intestinal protein formation. Front Microbiol 2016;7:713.
[16] Yang JM, Yu K, Donaldson GP, D’Astoli GG, Ann PA, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015;161(2):264–76. Erratum in: Cell 2015;163(1):258.
[17] Wibkinson WR, Anfora AF, Liu J, Schultz PG, Lesley SA, Peters EC, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009;106(10):3698–703.
[18] Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008;105(6):2117–22.
[19] Antharam VC, McEwen DC, Garrett JJ, Dossey AT, Li EC, Kozlov AN, et al. An integrative metabolomic and microbiome analysis identified specific gut microbiota associated with fecal cholesterol and coprostanol in Clostridium difficile infection. PLoS One 2016;11(2):e0148824.
[20] O’Connor A, O’Meara CA, Ford AC, P. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. Epub 2017 Jan 5.
[21] Komitou U, Fujita M, Gattini N, Morishi K, Sasajima J, et al. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun 2016;7:12365.
[22] Kleinn KS, Recco RA, Catalano MT, Edberg SC, Casey JI, Stiebigel NH. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med 1977;297(15):800–2.
[23] Ruoff KJ, Miller SL, Garnier CV, Ferraro MJ, Caldwell SB. Bacteremia with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol 1989;27(2):305–8.
[24] Huang QJ, Zheng GF, Sumanac K, Irvine JE, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003;125(6):1636–44.
[25] Martin HM, Campbell BJ, Hart CA, Mupofu C, Nayar M, Singh R, et al. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology 2004;127(1):80–93.
[26] Arthur JC, Jolin C. The struggle within: microbial influences on colorectal cancer. Inflam Bowel Dis 2011;17(1):396–409.
[27] Bellantani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int 2017;37(Suppl 1):81–4.
[28] Seto WK, Yuen MF. Non-alcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol 2017;52(2):164–74.
[29] Henaow-Meja J, E Ilan E, H, Lao H, Melah WZ, Sroug T, et al. lnflammasm mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482(7384):179–85.
[30] Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:32002.
[31] Le Roy T, Ilops M, Lepeage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intesti-
nal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013;62(5):787–94.

[32] Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013;58(1):120–1.

[33] Raes J, Ahmed A, Bel levie PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal microbiota and volatile organic compound metabolism in obese humans with nonalcoholic fatty liver disease. Clin. Gastroenterol Hepatol 2013;11(9):1708–13.

[34] Zhu L, Baker SS, Gill C, Liu W, Alkhoury B, Baker RD, et al. Characterization of gut microbiomes in nonobese diabetic (NOD) mice: a connection between endogenous alcohol and NASH. Hepatology 2013;57(2):601–9.

[35] Bordenave L, Muel lerer JR, Flacher M, Flah e S, A ra guo T, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63(3):764–75.

[36] Turlbau ng P, Ley E, Mahowald MA, Magrini V, Mardis ER, Gordon JJ. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444(7122):1027–31.

[37] Perry RJ, Bengt e L, Nair GM, Zhang D, Cardone RL, et al. Acetate mediates a microbiota-driven β-cell axis to promote metabolic syndrome. Nature 2016;534(7606):213–7.

[38] Cani PD, Dev eeer C, Delzenne NM. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br J Nutr 2004;92(3):521–6.

[39] Cani PD, Amar J, Igles eas MA, P oggi M, K nauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56(7):1761–72.

[40] Maslowski KM, Vieira AT, Ng K, Kra cji J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor CCR4. Nature 2009;461(7268):1282–6.

[41] Ruhl M, Cas af ont P, Cre FA, Jovin M, P oimp S, Mayorga E, Margarita A, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-α expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007;17(10):1374–80.

[42] Rivera CA, Adego bye PA, van Rooijen N, Tagaliduc A, Allman M, Wallace M, Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. Hepatol 2007;47(4):571–9.

[43] Sabaté JM, Pouét P, Harnois S, Fe chler C, Misca S, Grossin M, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008;18(4):475–8.

[44] Miceli R, Palen za E, Da Torre G, Montalto M, Cammarota G, R icci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49(6):1877–87.

[45] Harte AL, da Silva NF, Creely SJ, McGee KC, Biliary T, Yous ef el-Elabd EM, et al. Elevated endotoxin levels in nonalcoholic fatty liver disease. J Inflamm (Lond) 2010;7:15.

[46] Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2016;31(1):213–21.

[47] Imaio K, Fujit a K, Yoneda M, N oziya Y, Ogawa Y, Shinohara Y, et al. Hyperactivity abnormality in mice. Neurogastroenterol Motil 2014;26(4):510–20.

[48] Turnbough P, Ley E, Mahowald MA, Magrini V, Mardis ER, Gordon JJ. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444(7122):1027–31.

[49] Perry RI, Bengt e L, Nair GM, Zhang D, Cardone RL, et al. Acetate mediates a microbiota-driven β-cell axis to promote metabolic syndrome. Nature 2016;534(7606):213–7.

[50] Cani PD, Dev eeer C, Delzenne NM. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br J Nutr 2004;92(3):521–6.

[51] Cani PD, Amar J, Igles eas MA, P oggi M, K nauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56(7):1761–72.

[52] Maslowski KM, Vieira AT, Ng K, Kra cji J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor CCR4. Nature 2009;461(7268):1282–6.

[53] Ruhl M, Cas af ont P, Cre FA, Jovin M, P oimp S, Mayorga E, Margarita A, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-α expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007;17(10):1374–80.

[54] Rivera CA, Adego bye PA, van Rooijen N, Tagaliduc A, Allman M, Wallace M, Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. Hepatol 2007;47(4):571–9.

[55] Sabaté JM, Pouét P, Harnois S, Fe chler C, Misca S, Grossin M, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008;18(4):475–8.

[56] Miceli R, Palen za E, Da Torre G, Montalto M, Cammarota G, R icci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49(6):1877–87.

[57] Harte AL, da Silva NF, Creely SJ, McGee KC, Biliary T, Yous ef el-Elabd EM, et al. Elevated endotoxin levels in nonalcoholic fatty liver disease. J Inflamm (Lond) 2010;7:15.

[58] Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2016;31(1):213–21.

[59] Imaio K, Fujit a K, Yoneda M, N oziya Y, Ogawa Y, Shinohara Y, et al. Hyperactivity abnormality in mice. Neurogastroenterol Motil 2014;26(4):510–20.

[60] Turnbough P, Ley E, Mahowald MA, Magrini V, Mardis ER, Gordon JJ. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444(7122):1027–31.

[61] Perry RI, Bengt e L, Nair GM, Zhang D, Cardone RL, et al. Acetate mediates a microbiota-driven β-cell axis to promote metabolic syndrome. Nature 2016;534(7606):213–7.

[62] Cani PD, Dev eeer C, Delzenne NM. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br J Nutr 2004;92(3):521–6.

[63] Cani PD, Amar J, Igles eas MA, P oggi M, K nauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56(7):1761–72.

[64] Maslowski KM, Vieira AT, Ng K, Kra cji J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor CCR4. Nature 2009;461(7268):1282–6.

[65] Ruhl M, Cas af ont P, Cre FA, Jovin M, P oimp S, Mayorga E, Margarita A, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-α expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007;17(10):1374–80.

[66] Rivera CA, Adego bye PA, van Rooijen N, Tagaliduc A, Allman M, Wallace M, Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. Hepatol 2007;47(4):571–9.

[67] Sabaté JM, Pouét P, Harnois S, Fe chler C, Misca S, Grossin M, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008;18(4):475–8.

[68] Miceli R, Palen za E, Da Torre G, Montalto M, Cammarota G, R icci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49(6):1877–87.

[69] Harte AL, da Silva NF, Creely SJ, McGee KC, Biliary T, Yous ef el-Elabd EM, et al. Elevated endotoxin levels in nonalcoholic fatty liver disease. J Inflamm (Lond) 2010;7:15.
microbiome composition and diversity. Science 2016;352(6285):565–9.

[87] Sokol H, Pigneur B, Warterlot L, Lakhari O, Bermudez-Humaran LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105(43):16731–6.

[88] Osborn DA, Sinn JK. Prebiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 2007;(4):CD006475.

[89] Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 2011;5(2):220–36.

[90] Kleessen B, Sykura B, Zunft HJ, Blaut M. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr 1997;65(5):1397–402.

[91] Brüssow H. Biome engineering—2020. Microb Biotechnol 2016;9(5):553–63.

[92] Cox MJ, Huang YJ, Fujimura KE, Liu JT, McKeen M, Boushey HA, et al. Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome. PLoS One 2010;5(1):e8745.

[93] Korpela K, Salonen A, Virta IJ, Kumpu M, Kekkonen RA, de Vos WM. Lactobacillus rhamnosus GG intake modifies preschool children's intestinal microbiota, alleviates penicillin-associated changes, and reduces antibiotic use. PLoS One 2016;11(4):e0154012.

[94] Zhao Y, Wu J, Li Jv, Zhou NY, Tang H, Wang Y. Gut microbiota composition modifies fecal metabolic profiles in mice. J Proteome Res 2013;12(6):2987–99.

[95] Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011;108(Suppl 1):4554–61.

[96] Karlsson FH, Ussery DW, Nielsen J, Nookaew I. A closer look at Bacteroides: phylogenetic relationship and genomic implications of a life in the human gut. Microb Ecol 2011;61(3):473–485.

[97] Jyothi KS, Malini KS, Mamata M, Rao BS. Anti-bacterial response of twelve plants of folk-lore medicine used against diabetis mellitus. J Phyto Res 2007;20:161–70.

[98] Eiseeman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44(5):854–9.

[99] van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368(5):407–15.

[100] Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2016;315(2):142–9.

[101] Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2013;4(2):125–35.

[102] Weingarden A, González A, Vázquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, et al. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome 2015;3:10.

[103] Millan B, Park H, Hotte N, Mathieu O, Burguieres P, Tompkins TA, et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis 2016;62(12):1479–86.